<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor IX, human plasma-derived: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor IX, human plasma-derived: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor IX, human plasma-derived: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="88578" href="/d/html/88578.html" rel="external">see "Factor IX, human plasma-derived: Drug information"</a> and <a class="drug drug_patient" data-topicid="88617" href="/d/html/88617.html" rel="external">see "Factor IX, human plasma-derived: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16264034"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AlphaNine SD;</li>
<li>Mononine [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871580"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Immunine VH</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F23324420"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462681"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (Christmas disease): </b>Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor IX 1 unit/kg will increase circulating factor IX levels by ~1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control or prevention of bleeding episodes or perioperative management:</b> IV: <b>Note:</b> Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, individualized incremental recovery using factor IX activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mononine:</p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor IX Units Required = body weight (in kg) x desired Factor IX level increase (% or units/dL) x 1 unit/kg per units/dL</p>
<p style="text-indent:-2em;margin-left:12em;">For example, for a 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 3 kg x 80% x 1 unit/kg per units/dL = 240 units</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment recommendations (WFH [Srivastava 2020]):</i>
<b>Note:</b> Ages vary by product; see product-specific labeling for approved ages. Factor IX level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent IV: The following recommendations reflect WFH guidelines for higher dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. If factor IX levels are available, subsequent doses should be based on the half-life of factor IX and on the recovery in an individual patient for a particular product.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; frequency in chart based on Mononine; if using different product, see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 60% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 20% to 40%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 18 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dop drugH1Div" id="F16318994"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (Christmas disease): </b>Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor IX 1 unit/kg will increase circulating factor IX levels by ~1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for</b>
<b>control or prevention of bleeding episodes or perioperative management:</b>
<b>Note: </b>Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, individualized incremental recovery using factor IX activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (ages vary by product; see product-specific labeling for approved ages): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor IX Units Required = body weight (in kg) x desired Factor IX level increase (% or units/dL) x 1 unit/kg per units/dL</p>
<p style="text-indent:-2em;margin-left:12em;">For example, for a 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 25 kg x 80% x 1 unit/kg per units/dL = 2,000 units</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment recommendations (WFH [Srivastava 2020]):</i>
<b>Note:</b> Ages vary by product; see product-specific labeling for approved ages. Factor IX level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: Infants, Children, and Adolescents: The following recommendations reflect WFH guidelines for higher dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. If factor IX levels are available, subsequent doses should be based on the half-life of factor IX and on the recovery in an individual patient for a particular product.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 60% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 20% to 40%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 30 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV infusion: Limited data available: Infants, Children, and Adolescents: <b>Note: </b>In general, administration of factor IX 7.5 units/kg/hour will increase circulating factor IX levels by 1 unit/mL (Prelog 2016).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Control and prevention of bleeding episodes and perioperative management: </i>
<b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions (Batorova 2002; Hoots 2003; Morfini 2008; Poon 2012; Prelog 2016; WFH [Srivastava 2020]). Evidence supporting the use of continuous infusion is primarily with Mononine (Hoots 2003).</p>
<p style="text-indent:-2em;margin-left:14em;">Following initial bolus to achieve the desired factor IX level (Poon 2012): Initial dosing: 4 to 6 units/kg/hour; adjust dose based on frequent factor IX assays and calculation of factor IX clearance at steady-state using the following equations:</p>
<p style="text-indent:-2em;margin-left:14em;">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour)/(plasma Factor IX level in units/<b>mL)</b></p>
<p style="text-indent:-2em;margin-left:14em;">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:14em;">The median reported dose in postoperative patients (7 to 85 years) was 3.84 units/kg/hour (range: 1.74 to 7.3 units/kg/hour) (Hoots 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Maintain factor IX trough levels &gt;3% to 5% or higher as clinically indicated (WFH [Srivastava 2020]). Dose should be individualized; dose intensity should take into account disease severity, patient's activity and lifestyle, and pharmacokinetic properties of product and should be adjusted if breakthrough bleeding occurs. See guidelines for in-depth discussion of risks and benefits of each dosing approach.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">High dose: 40 to 60 units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermediate dose: 20 to 40 units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Low dose: 10 to 15 units/kg/dose 2 times weekly. <b> Note: </b>Low dose prophylaxis may be used in young patients as initial therapy; close monitoring is required since patients are at a higher risk for bleeding until escalation occurs.</p></div>
</div>
</div>
<div class="block doa drugH1Div" id="F16321187"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="88578" href="/d/html/88578.html" rel="external">see "Factor IX, human plasma-derived: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98495059-e110-44f0-ad91-ba0bd4d84e5d">Hemophilia B, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of other clotting factors besides factor IX or for reversal of anticoagulation due to vitamin K antagonists or other anticoagulants, for hemophilia A patients with factor VIII inhibitors, or for bleeding due to low levels of liver-dependent clotting factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing</i>: IV: </b>Utilize steps 1 to 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations (<b>Note</b>: IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Alphanine SD IVR</i>: 1 (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mononine IVR: </i>1.2 (White 1995).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Factor IX (Human) WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Type of hemorrhage or surgery</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Lower-dose practice pattern</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Higher-dose practice pattern</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>WFH = World Hemophilia Federation; (WFH [Srivastava 2020]).</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>May be longer if response is inadequate.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss: </b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>GI:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 70</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Factor IX units required = [(desired peak factor IX level − patient's baseline factor IX level) × body weight (kg)] / IVR</p>
<p style="text-indent:-2em;margin-left:10em;">(<b>Note:</b> Factor IX units are in units/dL)</p>
<p style="text-indent:-2em;margin-left:8em;">Example (Mononine) for 50 kg patient with desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 1.2:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = [(35 units/dL − 5 units/dL) × 50 kg] / 1.2 = 1,250 units factor IX</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 4:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing.<b> Note</b>: Frequency of administration must also take into consideration subsequent factor IX activity measurements and clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Factor IX (human) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="left">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="left">
<p style="text-indent:0em;">Major severity</p></th>
<th align="left">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="left">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Alphanine SD</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mononine</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">No recommendation</p></td>
<td align="left">
<p style="text-indent:0em;">Every 18 to 30 hours depending on patient half-life</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 18 to 30 hours depending on patient half-life</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Continuous infusion dosing</b> (Batorova 2002; Holme 2018; Hoots 2003; Ménart 1998; Poon 2012; Rickard 1995; Schulman 1995; WFH [Srivastava 2020]):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>Administer an initial bolus to achieve the desired factor IX level (see steps 1 to 3 under intermittent bolus dosing), then initiate continuous infusion of 4 to 6 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor IX clearance at steady-state using the below equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor IX level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) × (desired factor IX level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note</b>: With infusion dose increases, re-bolus should be considered to achieve target factor IX level more quickly. See steps 1 to 3 under "Intermittent IV bolus dosing" to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia B without inhibitors:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 40 to 60 factor IX units/kg twice weekly. Dosing should be tailored to ensure trough factor IX levels of at least 1% and preferably ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (WFH [Srivastava 2020]).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F16265557"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing, thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Burning sensation (in jaw/skull), chills, headache, lethargy, paresthesia, rigors</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Discomfort at injection site (stinging, burning), injection site reaction, pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Neck tightness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Allergic rhinitis, asthma, laryngeal edema, pulmonary disease</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever (including transient fever following rapid administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Angioedema, cerebral hemorrhage (intrathalamic [Douvas, 2004]), cyanosis, decreased therapeutic response, dyspnea, factor IX inhibitor development, hypotension, myocardial infarction (high doses), pulmonary embolism (high doses), superior vena cava syndrome (neonates [Douvas, 2004])</p></div>
<div class="block coi drugH1Div" id="F16264049"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">AlphaNine SD: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Mononine: Hypersensitivity to mouse protein</p>
<p style="text-indent:-2em;margin-left:2em;">Immunine VH [Canadian product]: Hypersensitivity to factor IX or any component of the formulation; known allergy to heparin; history of heparin-induced thrombocytopenia; disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis</p></div>
<div class="block war drugH1Div" id="F16264050"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis; risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX). Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma. Despite purification methods (AlphaNine SD - solvent detergent treated/virus filtered; Mononine - virus filtered); products may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Contains <b>nondetectable levels of factors II, VII, and X.</b> Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX. In addition, factor IX concentrate is <b>NOT INDICATED </b>for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), hemophilia A patients with factor VIII inhibitors, or patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with factor IX inhibitors and a history of allergic reactions to therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878787"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution when administering to neonates; the safety and efficacy of continuous infusion administration has not been established; thrombotic events have been reported in patients receiving continuous infusion of recombinant Factor IX through a central venous catheter, including life-threatening superior vena cava syndrome in neonates.</p></div>
<div class="block dosfc drugH1Div" id="F25573583"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F16321198"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AlphaNine SD: 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea) [contains heparin, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mononine: 1000 units (1 ea [DSC]) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F16264037"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570473"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (AlphaNine SD Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871581"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Immunine VH: 720 UNIT (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614530"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV administration only; plastic syringes are recommended for use with Mononine per the manufacturer; use administration sets/tubing provided by manufacturer (if provided). Solution should be infused at room temperature. With patients who have had allergic reactions during factor IX infusion, administration of antihistamine prior to infusion may be necessary (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV: Should be infused <b>slowly over several minutes</b>: Rate of administration should be determined by the response and comfort of the patient.</p>
<p style="text-indent:-2em;margin-left:4em;">AlphaNine SD: Administer IV at a rate not exceeding 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Mononine: Administer IV at a rate of ~2 mL/minute. Administration rates of up to 225 <b>units</b>/minute have been regularly tolerated without incident (when reconstituted as directed to ~100 units/mL).</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: Limited data available. Evidence supporting the use of continuous infusion is primarily with Mononine. Continuous infusion may be administered either as the reconstituted solution or further diluted in NS; diluted solution should be prepared every 12 hours (Hoots 2003).</p></div>
<div class="block adm drugH1Div" id="F16321188"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV intermittent bolus:</b> IV administration only: Should be infused <b>slowly over several minutes</b>: Rate of administration should be determined by the response and comfort of the patient. Solution should be infused at room temperature.</p>
<p style="text-indent:-2em;margin-left:4em;">AlphaNine SD: Administer IV at a rate not exceeding 10 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Mononine: Administer IV at a rate of ~2 mL/minute (when reconstituted as directed to ~100 units/mL). Administration rates of up to 225 <b>units</b>/minute have been regularly tolerated without incident.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV continuous infusion:</b> Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (Batorova 2002; Holme 2018; Hoots 2003; Ménart 1998; Poon 2012; Rickard 1995; Schulman 1995; WFH [Srivastava 2020]).</p></div>
<div class="block sts drugH1Div" id="F16265579"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">When stored at refrigerator temperature, 2°C to 8°C (36°F to 46°F), factor IX is stable for the period indicated by the expiration date on its label. Avoid freezing which may damage container for the diluent. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AlphaNine SD: May also be stored at room temperature not to exceed 30°C (86°F) for up to 1 month. Reconstituted solution should be used within 3 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mononine: May also be stored at room temperature not to exceed 25°C (77°F) for up to 1 month. Reconstituted solution should be at room temperature and used within 3 hours of preparation.</p></div>
<div class="block usep drugH1Div" id="F53571059"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) (Mononine: FDA approved in all ages; AlphaNine SD: FDA approved in ages &gt;16 years and adults).</p></div>
<div class="block mst drugH1Div" id="F16264032"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Factor IX may be confused with Factor IX Complex </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16369064"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16369062"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F16264048"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia B may have an increased bleeding risk following abortion, invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor IX levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor IX levels remain stable during pregnancy, factor IX replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor IX concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor IX concentrate is indicated to increase factor IX during pregnancy, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53571060"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Factor IX levels (measure 15 to 30 minutes after infusion to verify expected factor IX activity of the calculated doses) (WFH [Srivastava 2020]), signs of hypersensitivity reaction, disseminated intravascular coagulation, and thrombosis. Screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days, or after recurrent bleeds despite adequate factor IX replacement; all patients should have factor IX inhibitors screened every 6 to 12 months after therapy is initiated and then annually (WFH [Srivastava 2020]).</p></div>
<div class="block rerp drugH1Div" id="F53570420"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia (WFH [Srivastava 2020]):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F16265581"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>
<div class="block phk drugH1Div" id="F16265654"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: IX component: ~21 to 25 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059525"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Berinin p | Factor ix grifols | Immunine | Octanine f | Protromplex total tim 4 | Replenine vf</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Faktor ix | Haemonine</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Monofix | Tbsf high purity factor IX concentrate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Facteur ix conc. croix rouge | Factor ix solvent | Mononine | Nonafact</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aimafix di | Immunine | Octanine f | Prothromplex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Immunine | Mononine | Octanine f</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Octanine | Octanine f</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Berinin p | Betafact | Haemonine | Immunine | Nanotiv | Octanine | Octanine f | Replenine vf</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bebulin tim | Immunine | Mononine | Octanine f</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Berinin hs ix | Berinin p | Betafact | Haemonine | Immunine | Mononine | Octanine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Immunine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bebulin tim | Haemonine | Immunine | Octanine</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Octanine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bebulin tim | Immunine stim plus | Mononine | Octanine | Proplex t</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bemofil | F ix | Octanine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betafact | Mononine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Haemonine | Ht defix | Mononine | Prothromplex | Replenine vf</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Betafact | Mononine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Monofix-Vf</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Nanotiv</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bebulin | Bebulin tim | Berinin p | Betafact | Immunine ix | Mononine | Octanine f</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nonafact | Octanine f</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mononine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aimafix di | Alphanine | Fixnove | Haemobionine | Immunine stim plus | Ixed | Mononine | Octanine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Christmassin m | Novact | Novact m fujisawa | Novact-m</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Facnyne</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bebulin tim | Immunine | Octanine | Replenine vf</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mononine | Octanine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bebulin tim | Haemonine | Octanine | Replenine faktor ix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alphanine | Berinin p | Betafact | Immunine | Kedrifix | Octanine f | Replenine | Replenine vf</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Octanine f | Profilnine sd | Replenine vf</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Immunine | Immunonine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Faktor IX nmd | Immunine | Nanotiv | Octanine f</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Octanine f | Replenine vf</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Immunine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alphanine sd | Bebulin | Bebulin vh | Mononine | Profilnine sd | Proplex t</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Immunine | Mononine</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Berinin p | Factor ix grifols | Octanine f</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Immunine | Octanine f</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agemfil b | Immunine | Mononine | Octanine | Octanine f | Replenine | Replenine vf</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Octanine | Preconativ | Replenine vf</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Immunine | Mononine | Nanofix | Nanotiv</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Betafact | Immunine | Octanine f</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alphanine sd | Immunine | Profilnine sd</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Betafact | Haemonine | Immunine | Mononine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Berinin p | Betafact | Immunine | Nonafact | Octanine f | Replenine | Replenine vf</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">High Purity Factor IX | Immunine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Immunine | Octanine f</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Immunine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Haemosolvate factor ix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  AlphaNine SD (coagulation factor IX [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22101176">
<a name="22101176"></a>Chi C, Kadir RA. Inherited bleeding disorders in pregnancy. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2012;26(1):103-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22101176/pubmed" id="22101176" target="_blank">22101176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15087956">
<a name="15087956"></a>Douvas MG, Monahan PE. Life-threatening thrombosis complicating the management of hepatic hemorrhage: anticoagulant treatment in a newborn with hemophilia B. <i>J Pediatr Hematol Oncol. 2004;26(4):258-263.</i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/15087956/pubmed" id="15087956" target="_blank">15087956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12614367">
<a name="12614367"></a>Hoots WK, Leissinger C, Stabler S, et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. <i>Haemophilia</i>. 2003;9(2):164-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/12614367/pubmed" id="12614367" target="_blank">12614367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ImmunineVH.1">
<a name="ImmunineVH.1"></a>Immunine VH (factor IX human) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19298378">
<a name="19298378"></a>Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/19298378/pubmed" id="19298378" target="_blank">19298378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16834731">
<a name="16834731"></a>Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a Taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/16834731/pubmed" id="16834731" target="_blank">16834731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9625577">
<a name="9625577"></a>Ménart C, Petit PY, Attali O, Massignon D, Dechavanne M, Négrier C. Efficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patients. <i>Am J Hematol</i>. 1998;58(2):110-116. doi:10.1002/(sici)1096-8652(199806)58:2&lt;110::aid-ajh4&gt;3.0.co;2-v<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/9625577/pubmed" id="9625577" target="_blank">9625577</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mononine (coagulation factor IX human) [prescribing information]. Kankakee, IL: CSL Behring LLC; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19105506">
<a name="19105506"></a>Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. <i>Blood Transfus</i>. 2008;6(Suppl 2):21–25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/19105506/pubmed" id="19105506" target="_blank">19105506</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26674820">
<a name="26674820"></a>Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. <i>Blood Transfus</i>. 2016;14(5):474‐480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/26674820/pubmed" id="26674820" target="_blank">26674820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214734">
<a name="27214734"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/27214734/pubmed" id="27214734" target="_blank">27214734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214317">
<a name="27214317"></a>Schulman S, Gitel S, Zivelin A, et al. The feasibility of using concentrates containing factor IX for continuous infusion. <i>Haemophilia</i>. 1995;1(2):103-110. doi:10.1111/j.1365-2516.1995.tb00048.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/27214317/pubmed" id="27214317" target="_blank">27214317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776238">
<a name="22776238"></a>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47. doi:10.1111/j.1365-2516.2012.02909.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22776238/pubmed" id="22776238" target="_blank">22776238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9873771">
<a name="9873771"></a>Varon D and Martinowitz U, "Continuous Infusion Therapy in Haemophilia," <i>Haemophilia</i>, 1998, 4(4):431-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/9873771/pubmed" id="9873771" target="_blank">9873771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7482403">
<a name="7482403"></a>White GC 2nd, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. <i>Thromb Haemost</i>. 1995;73(5):779-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/7482403/pubmed" id="7482403" target="_blank">7482403</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 93440 Version 147.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
